LeMaitre Vascular (NASDAQ:LMAT) Upgraded to “Buy” at Wall Street Zen

LeMaitre Vascular (NASDAQ:LMAT) was upgraded by stock analysts at Wall Street Zen from a “hold” rating to a “buy” rating in a note issued to investors on Saturday.

Several other equities research analysts have also issued reports on LMAT. Zacks Research upgraded shares of LeMaitre Vascular from a “hold” rating to a “strong-buy” rating in a report on Monday, April 13th. Citizens Jmp upped their price target on shares of LeMaitre Vascular from $118.00 to $127.00 and gave the company a “market outperform” rating in a report on Wednesday, May 6th. Wells Fargo & Company increased their price objective on shares of LeMaitre Vascular from $94.00 to $104.00 and gave the stock an “equal weight” rating in a research report on Wednesday, May 6th. Weiss Ratings downgraded shares of LeMaitre Vascular from a “buy (b)” rating to a “buy (b-)” rating in a research note on Tuesday. Finally, Barrington Research restated an “outperform” rating and set a $120.00 target price on shares of LeMaitre Vascular in a research report on Wednesday, June 3rd. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and three have issued a Hold rating to the company’s stock. According to MarketBeat.com, LeMaitre Vascular currently has an average rating of “Moderate Buy” and a consensus price target of $112.60.

LeMaitre Vascular Stock Performance

NASDAQ:LMAT opened at $102.88 on Friday. The firm has a market capitalization of $2.35 billion, a PE ratio of 37.96, a PEG ratio of 2.86 and a beta of 0.52. The stock’s fifty day moving average is $98.79 and its 200 day moving average is $97.19. LeMaitre Vascular has a fifty-two week low of $79.00 and a fifty-two week high of $118.01. The company has a debt-to-equity ratio of 0.42, a quick ratio of 12.20 and a current ratio of 14.32.

LeMaitre Vascular (NASDAQ:LMAT) last posted its quarterly earnings data on Tuesday, May 5th. The medical instruments supplier reported $0.68 EPS for the quarter, topping the consensus estimate of $0.66 by $0.02. LeMaitre Vascular had a net margin of 24.35% and a return on equity of 15.36%. The company had revenue of $66.55 million during the quarter, compared to analyst estimates of $66.67 million. During the same period in the previous year, the firm earned $0.48 earnings per share. LeMaitre Vascular’s quarterly revenue was up 11.1% compared to the same quarter last year. LeMaitre Vascular has set its FY 2026 guidance at 2.930-3.080 EPS and its Q2 2026 guidance at 0.790-0.840 EPS. On average, sell-side analysts anticipate that LeMaitre Vascular will post 3 earnings per share for the current year.

Insiders Place Their Bets

In other LeMaitre Vascular news, Director Bridget A. Ross sold 5,044 shares of the company’s stock in a transaction dated Thursday, May 7th. The shares were sold at an average price of $111.10, for a total value of $560,388.40. Following the transaction, the director directly owned 3,942 shares in the company, valued at $437,956.20. This represents a 56.13% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Trent G. Kamke sold 2,928 shares of the firm’s stock in a transaction that occurred on Friday, May 8th. The stock was sold at an average price of $107.00, for a total transaction of $313,296.00. Following the transaction, the insider directly owned 3,749 shares in the company, valued at approximately $401,143. This trade represents a 43.85% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 54,453 shares of company stock worth $5,906,174 in the last three months. Corporate insiders own 7.40% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of LMAT. Royal Bank of Canada grew its position in shares of LeMaitre Vascular by 1.5% during the 1st quarter. Royal Bank of Canada now owns 114,176 shares of the medical instruments supplier’s stock worth $9,579,000 after buying an additional 1,735 shares in the last quarter. AQR Capital Management LLC raised its holdings in shares of LeMaitre Vascular by 36.4% in the first quarter. AQR Capital Management LLC now owns 27,878 shares of the medical instruments supplier’s stock valued at $2,339,000 after acquiring an additional 7,445 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in shares of LeMaitre Vascular by 4.7% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 12,078 shares of the medical instruments supplier’s stock valued at $1,013,000 after acquiring an additional 539 shares in the last quarter. Millennium Management LLC lifted its stake in LeMaitre Vascular by 119.8% in the first quarter. Millennium Management LLC now owns 211,222 shares of the medical instruments supplier’s stock worth $17,722,000 after acquiring an additional 115,141 shares during the period. Finally, Goldman Sachs Group Inc. lifted its stake in LeMaitre Vascular by 27.0% in the first quarter. Goldman Sachs Group Inc. now owns 262,445 shares of the medical instruments supplier’s stock worth $22,019,000 after acquiring an additional 55,804 shares during the period. 84.64% of the stock is currently owned by hedge funds and other institutional investors.

About LeMaitre Vascular

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company’s offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre’s product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.